VENUSREMNSEVenus Remedies Limited· PharmaceuticalsMinimalNeutral
Announced Tue, 19 May · 10:51 IST

Venus Remedies Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+9.1%1-day move
₹957.35
prior close
₹1005.20
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0+0.0+0.0+9.1+7.1+13.0+18.7+21.2+33.7+69.8+82.1+75.7
Up moveDown movePending
AI summary

Venus Remedies Limited submitted its yearly promoter disclosure under SEBI (SAST) Regulations. Promoter Pawan Chaudhary, on behalf of himself and the promoter group (including Manu Chaudhary, Peeyush Jain, Ashutosh Jain, Akshansh Chaudhary, and Sunev Pharma Solutions Pvt Ltd), declared that no encumbrance of shares was created or released during the period. The disclosure confirms that as of March 31, 2026, no equity shares held by the promoters or promoter group are pledged or encumbered. This is a standard nil-disclosure filing required annually under SEBI regulations.

Likely market impact

The nil encumbrance declaration is a positive signal for investors as it indicates promoters have not leveraged their shareholding through pledging, reducing risk of potential sudden selling pressure.